Neuroprotection against neonatal hypoxia/ischemia-induced cerebral cell death by prevention of calpain-mediated mGluR1alpha truncation.
Many cellular events are involved in ischemic neuronal death, and it has been difficult to identify those that play a critical role in the cascade triggered by lack of oxygen and glucose, although it has been widely recognized that overactivation of glutamate receptors represents one of the initiating factors. Different glutamate receptor antagonists, especially those for N-methyl-D-aspartate (NMDA) receptors, have achieved significant success in animal models of hypoxia/ischemia; however, these antagonists have failed in clinical trials. We previously reported that calpain-mediated truncation of metabotropic glutamate receptor 1alpha (mGluR1alpha) played a critical role in excitotoxicity, and that a TAT-mGluR1 peptide consisting of a peptide surrounding the calpain cleavage site of mGluR1alpha and the peptide transduction domain of the transactivating regulatory protein (TAT) of HIV was neuroprotective against excitotoxicity. In the present study we tested the effect of this peptide in in vitro and in vivo models of neonatal hypoxia/ischemia. TAT-mGluR1 peptide prevented oxygen/glucose deprivation- (OGD) and hypoxia/ischemia- (H/I) induced neuronal death in cultured hippocampal slices and neonatal rats, respectively. TAT-mGluR1 blocked H/I-induced mGluR1alpha degradation but had no effect on H/I-induced spectrin degradation, suggesting that neuroprotection was due to prevention of calpain-mediated mGluR1alpha truncation and not to calpain inhibition. Our results therefore suggest that mGluR1alpha truncation plays a critical role in neonatal hypoxia/ischemia and that blockade of this event may prevent the activation of many downstream cytotoxic cascades. Compared to glutamate receptor antagonists and general calpain inhibitors, TAT-mGluR1 may have limited side effects.
Neuroscience Program, University of Southern California, Los Angeles, CA 90089, USA.
Miou
M
Zhou
Wei
W
Xu
Guanghong
G
Liao
Xiaoning
X
Bi
Michel
M
Baudry
D000818:Animals; D000831:Animals, Newborn; D002154:Calpain / Q000378:metabolism*; D016923:Cell Death / Q000187:drug effects / Q000502:physiology; D004195:Disease Models, Animal; D005947:Glucose / Q000172:deficiency; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D020925:Hypoxia-Ischemia, Brain / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D009410:Nerve Degeneration / Q000209:etiology / Q000517:prevention & control*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D051381:Rats; D018094:Receptors, Metabotropic Glutamate / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D013049:Spectrin / Q000378:metabolism; D013997:Time Factors; D046509:Tissue Culture Techniques
D018696:Neuroprotective Agents; D018094:Receptors, Metabotropic Glutamate; D011993:Recombinant Fusion Proteins; C534738:TAT-mGluR1 peptide; C104077:metabotropic glutamate receptor type 1; D013049:Spectrin; D007770:L-Lactate Dehydrogenase; D002154:Calpain; D005947:Glucose